CN113491333A - Calcium chewable tablet added with water-soluble lutein and preparation method - Google Patents
Calcium chewable tablet added with water-soluble lutein and preparation method Download PDFInfo
- Publication number
- CN113491333A CN113491333A CN202110761773.1A CN202110761773A CN113491333A CN 113491333 A CN113491333 A CN 113491333A CN 202110761773 A CN202110761773 A CN 202110761773A CN 113491333 A CN113491333 A CN 113491333A
- Authority
- CN
- China
- Prior art keywords
- calcium
- parts
- water
- granules
- soluble lutein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 title claims abstract description 69
- 229960005375 lutein Drugs 0.000 title claims abstract description 67
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 title claims abstract description 67
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 title claims abstract description 67
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims abstract description 40
- 229910052791 calcium Inorganic materials 0.000 title claims abstract description 40
- 239000011575 calcium Substances 0.000 title claims abstract description 40
- 239000007910 chewable tablet Substances 0.000 title claims abstract description 22
- 229940068682 chewable tablet Drugs 0.000 title claims abstract description 15
- 235000012680 lutein Nutrition 0.000 title claims description 61
- 239000001656 lutein Substances 0.000 title claims description 61
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 title claims description 61
- 238000002360 preparation method Methods 0.000 title claims description 15
- 239000008267 milk Substances 0.000 claims abstract description 56
- 235000013336 milk Nutrition 0.000 claims abstract description 56
- 210000004080 milk Anatomy 0.000 claims abstract description 56
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 54
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 54
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 53
- 229960005069 calcium Drugs 0.000 claims abstract description 39
- 239000000843 powder Substances 0.000 claims abstract description 28
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 27
- 239000005913 Maltodextrin Substances 0.000 claims abstract description 27
- 229920002774 Maltodextrin Polymers 0.000 claims abstract description 27
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 27
- 239000001354 calcium citrate Substances 0.000 claims abstract description 27
- 239000004227 calcium gluconate Substances 0.000 claims abstract description 27
- 229960004494 calcium gluconate Drugs 0.000 claims abstract description 27
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 27
- 229940035034 maltodextrin Drugs 0.000 claims abstract description 27
- 235000010355 mannitol Nutrition 0.000 claims abstract description 27
- 239000000600 sorbitol Substances 0.000 claims abstract description 27
- 235000010216 calcium carbonate Nutrition 0.000 claims abstract description 26
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims abstract description 26
- 235000013927 calcium gluconate Nutrition 0.000 claims abstract description 26
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims abstract description 26
- 235000013337 tricalcium citrate Nutrition 0.000 claims abstract description 26
- 235000010356 sorbitol Nutrition 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims abstract description 15
- 239000008187 granular material Substances 0.000 claims description 36
- 239000011812 mixed powder Substances 0.000 claims description 36
- 239000003826 tablet Substances 0.000 claims description 27
- 235000002639 sodium chloride Nutrition 0.000 claims description 26
- 238000007873 sieving Methods 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 10
- 239000002994 raw material Substances 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- 238000007908 dry granulation Methods 0.000 claims description 6
- 238000004806 packaging method and process Methods 0.000 claims description 6
- 239000011780 sodium chloride Substances 0.000 claims description 6
- 238000003860 storage Methods 0.000 claims description 6
- 238000005303 weighing Methods 0.000 claims description 6
- 239000000463 material Substances 0.000 claims 3
- 235000008210 xanthophylls Nutrition 0.000 abstract description 6
- 210000000988 bone and bone Anatomy 0.000 abstract description 5
- 239000005556 hormone Substances 0.000 abstract description 2
- 229940088597 hormone Drugs 0.000 abstract description 2
- 230000036039 immunity Effects 0.000 abstract description 2
- 230000007774 longterm Effects 0.000 abstract description 2
- 231100000957 no side effect Toxicity 0.000 abstract description 2
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- 235000013402 health food Nutrition 0.000 abstract 1
- 239000003755 preservative agent Substances 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 5
- 206010064930 age-related macular degeneration Diseases 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000003078 antioxidant effect Effects 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000002780 macular degeneration Diseases 0.000 description 4
- 238000012549 training Methods 0.000 description 4
- 201000004569 Blindness Diseases 0.000 description 3
- 230000002354 daily effect Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003203 everyday effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007087 memory ability Effects 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000000149 penetrating effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001502 supplementing effect Effects 0.000 description 2
- 230000009182 swimming Effects 0.000 description 2
- 230000004393 visual impairment Effects 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 238000012347 Morris Water Maze Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000019007 dietary guidelines Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 238000010150 least significant difference test Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Inorganic Chemistry (AREA)
- Botany (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A calcium chewable tablet added with water-soluble xanthophyll comprises calcium carbonate, calcium citrate, calcium gluconate, sorbitol, milk powder, maltodextrin, D-mannitol, magnesium stearate, edible salt, milk essence and water-soluble xanthophyll. The health food does not contain any hormone, preservative or additive, has no side effect after long-term use, and can increase immunity, strengthen physique and strengthen bone.
Description
Technical Field
The invention relates to the field of health-care food, in particular to a calcium chewable tablet added with water-soluble lutein and a preparation method thereof.
Background
Calcium is the most abundant inorganic salt component in human body, is the main inorganic component of human bone and tooth, and is also the essential element for nerve transmission, muscle contraction, blood coagulation, hormone release and milk secretion, and also participates in human bodyNew and old generation Thanks toTherefore, calcium must be supplemented every day, and the deficiency or excess of calcium in human body affects growth and health.
The nutrition and health monitoring data of Chinese residents show that the average calcium intake of Chinese people is 366mg, which is far from 800mg of the daily recommended calcium intake of adults, the loss of calcium is easily caused by tobacco, wine, strong tea, coffee and high-salt diet, and the lack of calcium intake in vivo is easily caused by the deficiency of calcium intake. In the dietary guidelines of the Chinese population, it is recommended that each person preferably drinks 300ml of milk or a corresponding dairy product every day, but many Chinese people suffer from lactose intolerance, and many people have a wrong choice in calcium supplementation, and bone soup is considered to be capable of supplementing calcium, but in fact, more fat than calcium is contained in bone soup.
Some people cannot obtain enough calcium from food due to age, eating habits, diseases and the like, and in this case, calcium tablets are needed for supplementing the calcium in order to take enough calcium.
Xanthophyll is an excellent antioxidant, and can inhibit activity of active oxygen free radicals, prevent damage of active oxygen free radicals to normal cells, and prevent cardiovascular sclerosis, coronary heart disease, tumor, etc. caused by aging. The xanthophyll can inactivate singlet oxygen through physical or chemical quenching, thereby protecting organism from injury and enhancing immunity of organism. Lutein is also the only carotenoid component in which eye water crystals can be present, and many ophthalmic diseases are largely related to the lack of lutein.
Age Related Macular Degeneration (ARMD) is the first cause of blindness in people over the age of 65. 1300 million people in the United states suffer from ARMD symptoms, and an estimated 120 million people are afflicted with visual impairment due to the disease. With the increase of population over 65 years old, the number is estimated to double by 2050, and the prevention of vision loss and blindness caused by lesion of macular area of the aged eyeball is a unique function of lutein, and the possibility of reducing ARMD (anaplastic disease) is provided by increasing the lutein intake.
The difficulty of using lutein is that because of the characteristic of fat solubility, the lutein is difficult to be absorbed by human body and has low efficiency, and only 18 percent of lutein ester is metabolized into lutein by the action of digestive enzyme of human body when being taken orally.
Disclosure of Invention
The invention aims to provide calcium chewable tablets added with water-soluble lutein and a preparation method thereof, and particularly the added water-soluble lutein is lutein micro-emulsified powder which is prepared by converting an extremely unstable solid lutein raw material into chemically stable lutein through a formula stabilizing technology, can be fully dissolved in water, greatly improves the absorption efficiency of a human body, can effectively promote the absorption of calcium elements contained in a formula, and achieves the effect of achieving multiple purposes.
The invention realizes the purpose through the following technical scheme: a calcium chewable tablet added with water-soluble xanthophyll comprises calcium carbonate, calcium citrate, calcium gluconate, sorbitol, milk powder, maltodextrin, D-mannitol, magnesium stearate, edible salt and milk essence. Wherein the raw materials comprise the following components in parts by weight: 800 parts of 700-800 parts of calcium carbonate, 300 parts of 200-300 parts of calcium citrate, 400 parts of 300-400 parts of calcium gluconate, 80-100 parts of sorbitol, 90-170 parts of milk powder, 50-70 parts of maltodextrin, 80-100 parts of D-mannitol, 4-5 parts of magnesium stearate, 3-5 parts of edible salt, 1-3 parts of milk essence and 0.5-1 part of water-soluble lutein.
The preparation method of the calcium chewable tablet added with water-soluble lutein comprises the following steps:
s1, respectively sieving calcium carbonate, calcium citrate, calcium gluconate, sorbitol, milk powder, maltodextrin, D-mannitol, edible salt, milk essence, magnesium stearate and water-soluble lutein with 80 mesh sieve;
s2, weighing the sieved calcium carbonate, calcium citrate, calcium gluconate, sorbitol, milk powder, maltodextrin, D-mannitol, edible salt, milk essence, magnesium stearate and water-soluble lutein according to the formula for later use;
s3, mixing table salt, milk essence and water-soluble lutein to obtain mixed powder A;
s4, sorbitol, milk powder, maltodextrin, D-mannitol and the mixed powder A are fully mixed until the color is uniform, and mixed powder B is obtained;
s5, placing the calcium carbonate, the calcium citrate, the calcium gluconate and the mixed powder B into a mixer to be mixed for 20min to obtain total mixed powder;
s6, putting the total mixed powder into a dry granulation machine to prepare granules in a dry manner, sieving the granules by a 16-mesh sieve to obtain granules, mixing the granules and magnesium stearate by a mixer for 15min, and fully mixing until the color is uniform to obtain mixed granules;
s7, placing the mixed granules in a tablet press, adjusting the tablet weight to 1.2 g/tablet, tabletting to obtain tablets, and bottling;
and S8, carrying out external packaging, and storing the finished product at normal temperature.
The bottle specification of 72 g/bottle described in step S7.
The content of calcium in the prepared calcium chewable tablet product added with water-soluble lutein is not less than 88 mg/g.
The normal-temperature storage temperature in the step S8 is not higher than 20 ℃, and the relative humidity of air is not more than 60%.
The shelf life of the normal-temperature storage in the step S8 is 24 months.
The taking method comprises the following steps:
the preparation is administered 2 times daily, 2 tablets each time, to 4-17 years old people, adult, pregnant woman, and lactating woman.
Except for other descriptions, the percentages are mass percentages, and the sum of the content percentages of all the components is 100%.
The invention has the beneficial effects that:
the health-care functional food has the advantages of simple formula, simple and feasible preparation process, no side effect after long-term use, physique strengthening and bone strengthening.
Detailed Description
The technical solution of the present invention will be described in further detail by examples.
Example 1
In one example of the preparation method of the calcium chewable tablet added with water-soluble lutein,
the raw materials comprise: 700 parts of calcium carbonate, 200 parts of calcium citrate, 300 parts of calcium gluconate, 80 parts of sorbitol, 90 parts of milk powder, 50 parts of maltodextrin, 80 parts of D-mannitol, 4 parts of magnesium stearate, 3 parts of edible salt, 1.5 parts of milk essence and 0.7 part of water-soluble lutein.
The preparation method comprises the following steps:
s1, respectively sieving calcium carbonate, calcium citrate, calcium gluconate, sorbitol, milk powder, maltodextrin, D-mannitol, edible salt, milk essence, magnesium stearate and water-soluble lutein with 80 mesh sieve;
s2, weighing the sieved calcium carbonate, calcium citrate, calcium gluconate, sorbitol, milk powder, maltodextrin, D-mannitol, edible salt, milk essence, magnesium stearate and water-soluble lutein according to the formula for later use;
s3, mixing table salt, milk essence and water-soluble lutein to obtain mixed powder A;
s4, sorbitol, milk powder, maltodextrin, D-mannitol and the mixed powder A are fully mixed until the color is uniform, and mixed powder B is obtained;
s5, placing the calcium carbonate, the calcium citrate, the calcium gluconate and the mixed powder B into a mixer to be mixed for 20min to obtain total mixed powder;
s6, putting the total mixed powder into a dry granulation machine to prepare granules in a dry manner, sieving the granules by a 16-mesh sieve to obtain granules, mixing the granules and magnesium stearate by a mixer for 15min, and fully mixing until the color is uniform to obtain mixed granules;
s7, placing the mixed granules in a tablet press, adjusting the tablet weight to 1.2 g/tablet, tabletting to obtain tablets, and bottling;
and S8, carrying out external packaging, and storing the finished product at normal temperature.
Example 2
In another embodiment of the method for preparing calcium chewable tablets with water-soluble lutein of the present invention,
the raw materials comprise: 735 parts of calcium carbonate, 230 parts of calcium citrate, 325 parts of calcium gluconate, 90 parts of sorbitol, 130 parts of milk powder, 60 parts of maltodextrin, 90 parts of D-mannitol, 4.5 parts of magnesium stearate, 3.5 parts of edible salt, 2 parts of milk essence and 0.5 part of water-soluble lutein.
The preparation method comprises the following steps:
s1, respectively sieving calcium carbonate, calcium citrate, calcium gluconate, sorbitol, milk powder, maltodextrin, D-mannitol, edible salt, milk essence, magnesium stearate and water-soluble lutein with 80 mesh sieve;
s2, weighing the sieved calcium carbonate, calcium citrate, calcium gluconate, sorbitol, milk powder, maltodextrin, D-mannitol, edible salt, milk essence, magnesium stearate and water-soluble lutein according to the formula for later use;
s3, mixing table salt, milk essence and water-soluble lutein to obtain mixed powder A;
s4, sorbitol, milk powder, maltodextrin, D-mannitol and the mixed powder A are fully mixed until the color is uniform, and mixed powder B is obtained;
s5, placing the calcium carbonate, the calcium citrate, the calcium gluconate and the mixed powder B into a mixer to be mixed for 20min to obtain total mixed powder;
s6, putting the total mixed powder into a dry granulation machine to prepare granules in a dry manner, sieving the granules by a 16-mesh sieve to obtain granules, mixing the granules and magnesium stearate by a mixer for 15min, and fully mixing until the color is uniform to obtain mixed granules;
s7, placing the mixed granules in a tablet press, adjusting the tablet weight to 1.2 g/tablet, tabletting to obtain tablets, and bottling;
and S8, carrying out external packaging, and storing the finished product at normal temperature.
Example 3
In still another embodiment of the method for preparing calcium chewable tablets with water-soluble lutein according to the present invention,
the raw materials comprise: 765 parts of calcium carbonate, 280 parts of calcium citrate, 375 parts of calcium gluconate, 100 parts of sorbitol, 155 parts of milk powder, 70 parts of maltodextrin, 100 parts of D-mannitol, 5 parts of magnesium stearate, 4 parts of edible salt, 3 parts of milk essence and 1 part of water-soluble lutein.
The preparation method comprises the following steps:
s1, respectively sieving calcium carbonate, calcium citrate, calcium gluconate, sorbitol, milk powder, maltodextrin, D-mannitol, edible salt, milk essence, magnesium stearate and water-soluble lutein with 80 mesh sieve;
s2, weighing the sieved calcium carbonate, calcium citrate, calcium gluconate, sorbitol, milk powder, maltodextrin, D-mannitol, edible salt, milk essence, magnesium stearate and water-soluble lutein according to the formula for later use;
s3, mixing table salt, milk essence and water-soluble lutein to obtain mixed powder A;
s4, sorbitol, milk powder, maltodextrin, D-mannitol and the mixed powder A are fully mixed until the color is uniform, and mixed powder B is obtained;
s5, placing the calcium carbonate, the calcium citrate, the calcium gluconate and the mixed powder B into a mixer to be mixed for 20min to obtain total mixed powder;
s6, putting the total mixed powder into a dry granulation machine to prepare granules in a dry manner, sieving the granules by a 16-mesh sieve to obtain granules, mixing the granules and magnesium stearate by a mixer for 15min, and fully mixing until the color is uniform to obtain mixed granules;
s7, placing the mixed granules in a tablet press, adjusting the tablet weight to 1.2 g/tablet, tabletting to obtain tablets, and bottling;
and S8, carrying out external packaging, and storing the finished product at normal temperature.
The bottled package has a specification of 72 g/bottle.
The temperature of the normal-temperature storage is not higher than 20 ℃, and the relative humidity of the air is not more than 60%.
The shelf life of the storage at normal temperature is 24 months.
Example 4
Animal experiments were carried out on the calcium chewable tablets obtained by the preparation method of calcium chewable tablets with addition of water-soluble lutein described in examples 1 to 3:
60 SPF-grade 5-month-old male SAMP8 mice, 15 SPF-grade 5-month-old male SAMR1 mice with a weight of 27-41g were selected for the experiment, and after being adaptively bred for 7 days, the SAMP8 mice were randomly divided into 4 groups, and the test substances were administered to each group daily as follows:
normal control group (SAMR1 mice): a basal feed;
AD model group: a basal feed;
experimental group a: basal feed added with common lutein;
experimental group B: a basic feed for calcium chewable tablet containing water soluble xanthophyll is provided.
Continuously feeding for 8 weeks, performing learning and memory ability test by adopting a Morris water maze, wherein the diameter of the water maze is 100cm, the water depth is 21cm, black plastic spraying treatment is performed on the inner wall of the pool, the diameter of the platform is 9cm, the height of the platform is 20cm, the position of the platform cannot be seen by observing sleep with naked eyes, the water temperature is 21-22 ℃, the test lasts for 4 days, and training is performed for 4 times in a fixed time period every day.
Positioning navigation test: the mice were placed in a pool (without platform) for free swimming for 2min, so that they were familiar with the maze environment. When training begins, the platform is placed in the NE quadrant, and the mouse is placed into the pool facing the pool wall from any one of the four starting points of the pool wall. The free video recording system records the time (escape latency) when the mouse finds the platform and the swimming path, the mouse is respectively put into water from four different starting points (different quadrants) after 4 times of training, the mouse cannot find the platform after finding the platform or within 120s (the latency is recorded as 120s), and then the experimenter takes the mouse to the platform, takes a rest on the platform for 15s, and then carries out the next test. The average of the latency of 4 training sessions per day of mice was taken as the latency of the day of mice.
And (3) space exploration test: and after the detection of the incubation period is finished, carrying out a platform penetrating test on the mouse, namely removing the underwater platform and recording the times of the mouse penetrating the platform within 120 s.
After the water maze test is finished, the mouse is sacrificed, brain tissues are separated, the weight of the brain tissues to be tested is accurately weighed, and the weight (g): adding 9 times of physiological saline into the mixture with the volume (Ml) of 1:9, preparing 10% tissue homogenate under the ice bath condition, centrifuging at 10000r/min for 20min, taking supernatant, and detecting the activities of SOD, CAT and AchE and the contents of GSH and MDA according to the kit operation instructions. Protein content was determined by Coomassie Brilliant blue method.
SPSS17.0 statistical software is adopted for data analysis, experimental data are expressed by mean +/-standard deviation, variance analysis is adopted for comparison between multiple groups, LSD test is adopted for comparison between two groups, and P is less than 0.05 to indicate that the difference has statistical significance.
Test results show that the antioxidant capacity of SAMP8 is obviously lower than that of SAMR 1; the lutein can improve the activities of antioxidase (SOD and CAT) and antioxidant content (GSH) in SAMP8, and reduce MDA, thereby improving the antioxidant capacity of mice and reducing oxidative stress damage; the intervention effect of common lutein is lower than that of water-soluble lutein.
The test result shows that the food has certain effect of improving learning and memory ability, and is better than common lutein.
The oral toxicity LD50 of the water-soluble lutein mouse is more than 10g/kg, and the bioavailability of the water-soluble lutein is 8 times that of lutein ester according to the acute toxicity grading standard, and the water-soluble lutein is practically nontoxic.
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be able to cover the technical solutions and the inventive concepts of the present invention within the technical scope of the present invention.
Claims (7)
1. A calcium chewable tablet added with water-soluble lutein is characterized in that the calcium chewable tablet at least comprises calcium carbonate, calcium citrate, calcium gluconate, sorbitol, milk powder, maltodextrin, D-mannitol, magnesium stearate, edible salt, milk essence and water-soluble lutein; wherein the raw materials comprise the following components in parts by weight: 800 parts of 700-calcium carbonate-containing material, 300 parts of 200-calcium citrate-containing material, 400 parts of 300-calcium gluconate-containing material, 80-100 parts of sorbitol, 90-170 parts of milk powder, 50-70 parts of maltodextrin, 80-100 parts of D-mannitol, 4-5 parts of magnesium stearate, 3-5 parts of edible salt, 1-3 parts of milk essence and 0.5-1 part of water-soluble lutein.
2. The process for the preparation of calcium chewable tablets supplemented with water-soluble lutein according to claim 1, characterized by the following process steps:
s1, respectively sieving calcium carbonate, calcium citrate, calcium gluconate, sorbitol, milk powder, maltodextrin, D-mannitol, edible salt, milk essence, magnesium stearate and water-soluble lutein with 80 mesh sieve;
s2, weighing the sieved calcium carbonate, calcium citrate, calcium gluconate, sorbitol, milk powder, maltodextrin, D-mannitol, edible salt, milk essence, magnesium stearate and water-soluble lutein according to the formula for later use;
s3, mixing table salt, milk essence and water-soluble lutein to obtain mixed powder A;
s4, sorbitol, milk powder, maltodextrin, D-mannitol and the mixed powder A are fully mixed until the color is uniform, and mixed powder B is obtained;
s5, placing the calcium carbonate, the calcium citrate, the calcium gluconate and the mixed powder B into a mixer to be mixed for 20min to obtain total mixed powder;
s6, putting the total mixed powder into a dry granulation machine to prepare granules in a dry manner, sieving the granules by a 16-mesh sieve to obtain granules, mixing the granules and magnesium stearate by a mixer for 15min, and fully mixing until the color is uniform to obtain mixed granules;
s7, placing the mixed granules in a tablet press, adjusting the tablet weight to 1.2 g/tablet, tabletting to obtain tablets, and bottling;
and S8, carrying out external packaging, and storing the finished product at normal temperature.
3. The preparation method of the calcium chewable tablet added with water-soluble lutein according to claim 1, is characterized in that the raw materials comprise the following components in parts by weight: 700 parts of calcium carbonate, 200 parts of calcium citrate, 300 parts of calcium gluconate, 80 parts of sorbitol, 90 parts of milk powder, 50 parts of maltodextrin, 80 parts of D-mannitol, 4 parts of magnesium stearate, 3 parts of edible salt, 1.5 parts of milk essence and 0.7 part of water-soluble lutein,
the preparation method comprises the following steps:
s1, respectively sieving calcium carbonate, calcium citrate, calcium gluconate, sorbitol, milk powder, maltodextrin, D-mannitol, edible salt, milk essence, magnesium stearate and water-soluble lutein with 80 mesh sieve;
s2, weighing the sieved calcium carbonate, calcium citrate, calcium gluconate, sorbitol, milk powder, maltodextrin, D-mannitol, edible salt, milk essence, magnesium stearate and water-soluble lutein according to the formula for later use;
s3, mixing table salt, milk essence and water-soluble lutein to obtain mixed powder A;
s4, sorbitol, milk powder, maltodextrin, D-mannitol and the mixed powder A are fully mixed until the color is uniform, and mixed powder B is obtained;
s5, placing the calcium carbonate, the calcium citrate, the calcium gluconate and the mixed powder B into a mixer to be mixed for 20min to obtain total mixed powder;
s6, putting the total mixed powder into a dry granulation machine to prepare granules in a dry manner, sieving the granules by a 16-mesh sieve to obtain granules, mixing the granules and magnesium stearate by a mixer for 15min, and fully mixing until the color is uniform to obtain mixed granules;
s7, placing the mixed granules in a tablet press, adjusting the tablet weight to 1.2 g/tablet, tabletting to obtain tablets, and bottling;
and S8, carrying out external packaging, and storing the finished product at normal temperature.
4. The method for preparing calcium chewable tablet containing water-soluble lutein according to claim 2, wherein the bottle specification of step S7 is 72 g/bottle 4.
5. The method for preparing calcium chewable tablets containing water-soluble lutein according to claim 2, wherein the calcium content of the tablet product is ≧ 88 mg/g.
6. The method for preparing calcium chewable tablet containing water-soluble lutein according to claim 4, wherein the storage temperature at normal temperature in step S8 is not higher than 20 ℃ and the air relative humidity is not higher than 60%.
7. The method for preparing calcium chewable tablet containing water-soluble lutein according to claim 4, wherein the shelf life of normal temperature storage in step S8 is 24 months.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110761773.1A CN113491333A (en) | 2021-07-06 | 2021-07-06 | Calcium chewable tablet added with water-soluble lutein and preparation method |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110761773.1A CN113491333A (en) | 2021-07-06 | 2021-07-06 | Calcium chewable tablet added with water-soluble lutein and preparation method |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113491333A true CN113491333A (en) | 2021-10-12 |
Family
ID=77998132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110761773.1A Pending CN113491333A (en) | 2021-07-06 | 2021-07-06 | Calcium chewable tablet added with water-soluble lutein and preparation method |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113491333A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101606566A (en) * | 2008-06-18 | 2009-12-23 | 刁媛媛 | The preparation method and the application of a kind of functional chewing and mouthful disintegrating tablet candy |
| CN102038644A (en) * | 2010-12-23 | 2011-05-04 | 沈阳药科大学 | Lutein water-soluble powder and preparation process thereof |
| CN103083270A (en) * | 2013-02-25 | 2013-05-08 | 林继华 | Xanthophyll chewable tablet |
| CN106072545A (en) * | 2016-06-27 | 2016-11-09 | 北京康倍多生物科技有限公司 | The asthenopic xanthophyll chewable tablet of a kind of alleviation and preparation method |
| CN106674074A (en) * | 2016-12-30 | 2017-05-17 | 华宝香精股份有限公司 | Preparation method of water-soluble lutein |
| CN109044986A (en) * | 2018-07-23 | 2018-12-21 | 广州市范乐医药科技有限公司 | A kind of lutein complex capsule and preparation method thereof improving eyesight |
| US20190098924A1 (en) * | 2016-04-01 | 2019-04-04 | Dsm Ip Assets B.V. | New tablettable formulation of lutein and/or zeaxanthin |
| CN110810605A (en) * | 2019-12-02 | 2020-02-21 | 山东国和堂制药有限公司 | Sweet orange lutein ester tablet for children to eat |
-
2021
- 2021-07-06 CN CN202110761773.1A patent/CN113491333A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101606566A (en) * | 2008-06-18 | 2009-12-23 | 刁媛媛 | The preparation method and the application of a kind of functional chewing and mouthful disintegrating tablet candy |
| CN102038644A (en) * | 2010-12-23 | 2011-05-04 | 沈阳药科大学 | Lutein water-soluble powder and preparation process thereof |
| CN103083270A (en) * | 2013-02-25 | 2013-05-08 | 林继华 | Xanthophyll chewable tablet |
| US20190098924A1 (en) * | 2016-04-01 | 2019-04-04 | Dsm Ip Assets B.V. | New tablettable formulation of lutein and/or zeaxanthin |
| CN106072545A (en) * | 2016-06-27 | 2016-11-09 | 北京康倍多生物科技有限公司 | The asthenopic xanthophyll chewable tablet of a kind of alleviation and preparation method |
| CN106674074A (en) * | 2016-12-30 | 2017-05-17 | 华宝香精股份有限公司 | Preparation method of water-soluble lutein |
| CN109044986A (en) * | 2018-07-23 | 2018-12-21 | 广州市范乐医药科技有限公司 | A kind of lutein complex capsule and preparation method thereof improving eyesight |
| CN110810605A (en) * | 2019-12-02 | 2020-02-21 | 山东国和堂制药有限公司 | Sweet orange lutein ester tablet for children to eat |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20010002269A1 (en) | Multi-phase food & beverage | |
| EP1913943B1 (en) | Prophylactic or therapeutic composition for hemoglobinuria or myoglobinuria | |
| US7932288B2 (en) | Composition for relieving subjective symptoms of fatigue | |
| JPH06500552A (en) | Calcium and trace mineral supplements | |
| US20080286388A1 (en) | Pharmaceutical Composition and Non Dependence Coffee Comprising Edible Carboxylic Acid and/or Its Acid Salts and Coffeine | |
| CN102160664A (en) | Nutritious drink for children | |
| CN106722607A (en) | A kind of preparation method of mulberry jam | |
| CN105942506A (en) | Special medical application formula food suitable for patients suffering from liver diseases | |
| CN106138101B (en) | A kind of preparation method of chicken embryo placenta extract | |
| CN109288005B (en) | Composition with function of assisting in improving memory, application and preparation method thereof | |
| KR101859166B1 (en) | A composition for removing hangover comprising an herb extract including ginseng | |
| KR101642176B1 (en) | Composition for enhancing growth and reinforcing immunity | |
| WO2015137387A1 (en) | Muscle enhancing drug | |
| CA2519250C (en) | Therapeutic agent for diabetes mellitus | |
| CN113491333A (en) | Calcium chewable tablet added with water-soluble lutein and preparation method | |
| CN105901577A (en) | Nutritional agent for reinforcing brain, protecting eye and strengthening body and preparation method and application thereof | |
| CN110403112A (en) | A kind of preparation method of bubble orange juice | |
| JP2023154540A (en) | Composition for preventing or improving age-related hearing loss | |
| KR20180052514A (en) | A method for manufacturing low temperature aging garlic and composition for antifatigue comprising there of extract | |
| CN107439866A (en) | Matrimony vine chickpea plant nutrients beverage and its preparation technology | |
| JP2996313B2 (en) | Functional health food | |
| KR20010016591A (en) | A manufacturing of Rhodiola sachalinensis A. Bor and a use | |
| KR20180002157A (en) | A composition for removing hangover comprising an extract of Cinnamomum cassia Presl and cinnamomi petiole | |
| CN106819223A (en) | A kind of health-care milk tea and preparation method thereof | |
| US20040006139A1 (en) | Choline pyruvate, method for the production thereof, formulations containing choline pyruvate and the use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211012 |
|
| WD01 | Invention patent application deemed withdrawn after publication |